Human Tissue Factor (TF) AssayMax ELISA KitHuman Tissue Factor (TF) AssayMax ELISA Kit
Move your mouse over image or click to enlarge

Human Tissue Factor (TF) AssayMax ELISA Kit

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.

Cat# Size Price Qty Buy
ET1002-1 96 Well Plate £276.25

Additional Information

Property Value or Rating
Manufacturer Assaypro, LLC.
Product Type AssayMax™ ELISA Kits
Samples Serum, Cell Culture, Tissue Extract
Species Human
Reactivity Human
Assay Format Sandwich ELISA
Product Size 96 Well Plate
Range 12.5-400 pg/ml
Plex Number 1
Storage Refer to component labels for details
Entrez Gene 2152
Omim 134390
UniProt P13726
UniGene Hs.62192
Special Notes For Research Use Only, Not To Be Used For Diagnostic Purposes
References * Siddiqui FA et al. (2002) The presence and release of tissue factor from human platelets. Platelets 13(4):247-253 
* Jesmin S et al. (2004) Temporal changes in pulmonary expression of key procoagulant molecules in rabbits with endotoxin-induced acute lung injury: elevated expression levels of protease-activated receptors. Thromb Haemost. 92(5):966-979 
* Henriksson CE et al. (2005) Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. Thromb Haemost. 94(6):1236-44 
* Roth GA et al. (2006) Infection with a periodontal pathogen induces procoagulant effects in human aortic endothelial cells. Journal of Thrombosis and Haemostasis 4(10):2256-2261 
* Sawa H et al. (2006) Elevation of plasma tissue factor levels in patients with severe acute pancreatitis. J. Gastroenterol. 41(6):575-581 
* Emekli-Alturfan E et al. (2007) The Relation between Plasma Tissue Factor and Oxidized LDL Levels in Acute Coronary Syndromes. Pathophysiol Haemost Thromb. 36(6):290-297 
* Han J et al. (2008) An anticoagulant serine protease from the wasp venom of Vespa magnifica. Toxicon 51(5):914-922 
* He WJ et al. (2008) Activated protein C ratio, plasma tissue factor activity and activated factor VII in Chinese patients with coronary heart disease. Eur J Med Res. 13:47-51 
* Jiang DJ et al. (2009) Asymmetric dimethylarginine induces tissue factor expression in monocytes via NF-kappaB-dependent pathway: Role in acute coronary syndromes. Atherosclerosis 205(2):554-560 
* Teng YC et al. (2009) Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts. J. Perinat. Med. 37:343-348 
* Andersson E et al. (2010) Tissue factor in predicted severe acute pancreatitis. World J Gastroenterol 16(48): 6128-6134 
* Munuswamy-Ramanujam G et al. (2010) Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets. Thromb Haemost. 103(3):545-555 
* Strijbos MH et al. (2010) Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. European Journal of Cancer 46:2027-2035 
* Teng Y et al. (2010) The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients. Thrombosis Research 126(1):e41-e45 
* Watson T et al. (2010) Relationship of Indices of Inflammation and Thrombogenesis to Arrhythmia Burden in Paroxysmal Atrial Fibrillation. Chest. 137(4):869-876 
* Jiang WH et al. (2011) Regulatory role of RhoA/Rho kinase in the effect of fluvastatin on tumor necrosis factor-alpha induced expression of tissue factor. Afr. J. Pharm. Pharmacol. 5(12):1462-1466 
* Priya N et al. (2011) Characterization of a unique dihydropyrimidinone, ethyl 4-(4-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model. Journal of Pharmacy and Pharmacology 63(9):1175-1185 
* Santos M (2011) Contraindication of inflammation and traditional cardiovascular risk development of subclinical aterosclerosos. University of Lisbon, Ph.D. Thesis 
* Wang Y et al. (2011) Prediction of response to docetaxel therapy based on the presence of tmprssg2:erg fusion in circulating tumor cells. USPTO Patent Applicaton #: #20110166030 
* Xiong Y et al. (2011) Alternations of Maternal and Cord Plasma Hemostasis in Preeclampsia Before and After Delivery. Hypertens Pregnancy. 30(3):347-358 
* Fernandez-Cadenas I et al. (2012) IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke. Stroke. 43(10):2659-2665 
* Santos MJ (2012) Early Vascular Alterations in SLE and RA Patients--A Step towards Understanding the Associated Cardiovascular Risk. PLoS One. 7(9):e44668.doi: 10.1371/journal.pone.0044668 
* Zhu H et al. (2012) Activation of coagulation, anti-coagulation, fibrinolysis and the complement system in patients with urticaria. Asian Pac J Allergy Immunol 31:43-50 
* Kohno K et al. (2013) Therapeutic agent for inflammary diseases, containing adenosine N1-Oxide as an effective ingredient. Patent application: 20130165399 A1 
* Wang R et al. (2015) Simultaneous detection of peripheral mononuclear cell and plasma tissue factor expression for prevention and treatment of ischemic cardiocerebrovascular diseases. Int J Clin Exp Pathol 8(5):5674-5680 

" title="

* Siddiqui FA et al. (2002) The presence and release of tissue factor from human platelets. Platelets 13(4):247-253 
* Jesmin S et al. (2004) Temporal changes in pulmonary expression of key procoagulant molecules in rabbits with endotoxin-induced acute lung injury: elevated expression levels of protease-activated receptors. Thromb Haemost. 92(5):966-979 
* Henriksson CE et al. (2005) Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. Thromb Haemost. 94(6):1236-44 
* Roth GA et al. (2006) Infection with a periodontal pathogen induces procoagulant effects in human aortic endothelial cells. Journal of Thrombosis and Haemostasis 4(10):2256-2261 
* Sawa H et al. (2006) Elevation of plasma tissue factor levels in patients with severe acute pancreatitis. J. Gastroenterol. 41(6):575-581 
* Emekli-Alturfan E et al. (2007) The Relation between Plasma Tissue Factor and Oxidized LDL Levels in Acute Coronary Syndromes. Pathophysiol Haemost Thromb. 36(6):290-297 
* Han J et al. (2008) An anticoagulant serine protease from the wasp venom of Vespa magnifica. Toxicon 51(5):914-922 
* He WJ et al. (2008) Activated protein C ratio, plasma tissue factor activity and activated factor VII in Chinese patients with coronary heart disease. Eur J Med Res. 13:47-51 
* Jiang DJ et al. (2009) Asymmetric dimethylarginine induces tissue factor expression in monocytes via NF-kappaB-dependent pathway: Role in acute coronary syndromes. Atherosclerosis 205(2):554-560 
* Teng YC et al. (2009) Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts. J. Perinat. Med. 37:343-348 
* Andersson E et al. (2010) Tissue factor in predicted severe acute pancreatitis. World J Gastroenterol 16(48): 6128-6134 
* Munuswamy-Ramanujam G et al. (2010) Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets. Thromb Haemost. 103(3):545-555 
* Strijbos MH et al. (2010) Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. European Journal of Cancer 46:2027-2035 
* Teng Y et al. (2010) The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients. Thrombosis Research 126(1):e41-e45 
* Watson T et al. (2010) Relationship of Indices of Inflammation and Thrombogenesis to Arrhythmia Burden in Paroxysmal Atrial Fibrillation. Chest. 137(4):869-876 
* Jiang WH et al. (2011) Regulatory role of RhoA/Rho kinase in the effect of fluvastatin on tumor necrosis factor-alpha induced expression of tissue factor. Afr. J. Pharm. Pharmacol. 5(12):1462-1466 
* Priya N et al. (2011) Characterization of a unique dihydropyrimidinone, ethyl 4-(4-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model. Journal of Pharmacy and Pharmacology 63(9):1175-1185 
* Santos M (2011) Contraindication of inflammation and traditional cardiovascular risk development of subclinical aterosclerosos. University of Lisbon, Ph.D. Thesis 
* Wang Y et al. (2011) Prediction of response to docetaxel therapy based on the presence of tmprssg2:erg fusion in circulating tumor cells. USPTO Patent Applicaton #: #20110166030 
* Xiong Y et al. (2011) Alternations of Maternal and Cord Plasma Hemostasis in Preeclampsia Before and After Delivery. Hypertens Pregnancy. 30(3):347-358 
* Fernandez-Cadenas I et al. (2012) IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke. Stroke. 43(10):2659-2665 
* Santos MJ (2012) Early Vascular Alterations in SLE and RA Patients--A Step towards Understanding the Associated Cardiovascular Risk. PLoS One. 7(9):e44668.doi: 10.1371/journal.pone.0044668 
* Zhu H et al. (2012) Activation of coagulation, anti-coagulation, fibrinolysis and the complement system in patients with urticaria. Asian Pac J Allergy Immunol 31:43-50 
* Kohno K et al. (2013) Therapeutic agent for inflammary diseases, containing adenosine N1-Oxide as an effective ingredient. Patent application: 20130165399 A1 
* Wang R et al. (2015) Simultaneous detection of peripheral mononuclear cell and plasma tissue factor expression for prevention and treatment of ischemic cardiocerebrovascular diseases. Int J Clin Exp Pathol 8(5):5674-5680 

" target="_blank">

* Siddiqui FA et al. (2002) The presence and release of tissue factor from human platelets. Platelets 13(4):247-253 
* Jesmin S et al. (2004) Temporal changes in pulmonary expression of key procoagulant molecules in rabbits with endotoxin-induced acute lung injury: elevated expression levels of protease-activated receptors. Thromb Haemost. 92(5):966-979 
* Henriksson CE et al. (2005) Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. Thromb Haemost. 94(6):1236-44 
* Roth GA et al. (2006) Infection with a periodontal pathogen induces procoagulant effects in human aortic endothelial cells. Journal of Thrombosis and Haemostasis 4(10):2256-2261 
* Sawa H et al. (2006) Elevation of plasma tissue factor levels in patients with severe acute pancreatitis. J. Gastroenterol. 41(6):575-581 
* Emekli-Alturfan E et al. (2007) The Relation between Plasma Tissue Factor and Oxidized LDL Levels in Acute Coronary Syndromes. Pathophysiol Haemost Thromb. 36(6):290-297 
* Han J et al. (2008) An anticoagulant serine protease from the wasp venom of Vespa magnifica. Toxicon 51(5):914-922 
* He WJ et al. (2008) Activated protein C ratio, plasma tissue factor activity and activated factor VII in Chinese patients with coronary heart disease. Eur J Med Res. 13:47-51 
* Jiang DJ et al. (2009) Asymmetric dimethylarginine induces tissue factor expression in monocytes via NF-kappaB-dependent pathway: Role in acute coronary syndromes. Atherosclerosis 205(2):554-560 
* Teng YC et al. (2009) Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts. J. Perinat. Med. 37:343-348 
* Andersson E et al. (2010) Tissue factor in predicted severe acute pancreatitis. World J Gastroenterol 16(48): 6128-6134 
* Munuswamy-Ramanujam G et al. (2010) Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets. Thromb Haemost. 103(3):545-555 
* Strijbos MH et al. (2010) Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. European Journal of Cancer 46:2027-2035 
* Teng Y et al. (2010) The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients. Thrombosis Research 126(1):e41-e45 
* Watson T et al. (2010) Relationship of Indices of Inflammation and Thrombogenesis to Arrhythmia Burden in Paroxysmal Atrial Fibrillation. Chest. 137(4):869-876 
* Jiang WH et al. (2011) Regulatory role of RhoA/Rho kinase in the effect of fluvastatin on tumor necrosis factor-alpha induced expression of tissue factor. Afr. J. Pharm. Pharmacol. 5(12):1462-1466 
* Priya N et al. (2011) Characterization of a unique dihydropyrimidinone, ethyl 4-(4-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model. Journal of Pharmacy and Pharmacology 63(9):1175-1185 
* Santos M (2011) Contraindication of inflammation and traditional cardiovascular risk development of subclinical aterosclerosos. University of Lisbon, Ph.D. Thesis 
* Wang Y et al. (2011) Prediction of response to docetaxel therapy based on the presence of tmprssg2:erg fusion in circulating tumor cells. USPTO Patent Applicaton #: #20110166030 
* Xiong Y et al. (2011) Alternations of Maternal and Cord Plasma Hemostasis in Preeclampsia Before and After Delivery. Hypertens Pregnancy. 30(3):347-358 
* Fernandez-Cadenas I et al. (2012) IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke. Stroke. 43(10):2659-2665 
* Santos MJ (2012) Early Vascular Alterations in SLE and RA Patients--A Step towards Understanding the Associated Cardiovascular Risk. PLoS One. 7(9):e44668.doi: 10.1371/journal.pone.0044668 
* Zhu H et al. (2012) Activation of coagulation, anti-coagulation, fibrinolysis and the complement system in patients with urticaria. Asian Pac J Allergy Immunol 31:43-50 
* Kohno K et al. (2013) Therapeutic agent for inflammary diseases, containing adenosine N1-Oxide as an effective ingredient. Patent application: 20130165399 A1 
* Wang R et al. (2015) Simultaneous detection of peripheral mononuclear cell and plasma tissue factor expression for prevention and treatment of ischemic cardiocerebrovascular diseases. Int J Clin Exp Pathol 8(5):5674-5680 

Related Documents